In a study appearing online on July 14 in advance of print publication of the August 1 issue of the Journal of Clinical Investigation , Joseph Kovacs and colleagues from the NIH use cutting-edge in vivo labeling techniques to show that intermittent administration of IL-2 to HIV-infected patients induces a high level of proliferation of both CD4 and CD8 cells, followed by a remarkably prolonged survival of only the CD4 cells.
These results help explain the preferential CD4 cell increases seen in patients receiving intermittent IL-2 therapy and provide new insight into the biological activities of exogenously administered IL-2.
Title: Induction of Prolonged Survival of CD4+ T Lymphocytes by Intermittent IL-2 Therapy in Patients with HIV Infection
AUTHOR CONTACT:
Joseph A. Kovacs
National Institutes Of Health, Bethesda, MD USA
Phone: 301-496-9907; Fax: 301-402-1213; E-mail: jkovacs@nih.gov
View the PDF of this article at: https://www.the-jci.org/article.php?id=23196
Journal of Clinical Investigation